Webinars

On Tuesday March 19, we’ll kick off our 2024- webinars with a dive into AI in Biotech & Healthtech.

Sara Reekmans and Youri de Groote from Arnold & Siedsma speak about the impact of Artificial Intelligence in R&D, among other things. How do you apply AI to improve collaboration between scientists, companies, and patients/ clients? And how does AI provide new insights into complex medical data that form the basis for new medicines and therapies?

Arnold & Siedsma specialises in intellectual property rights. From the definition of patents to the registration and protection of brands, models, and other rights. We help you make a success of your idea or invention.

On Tuesday April 16, 12.00 – 13.00, Jeff Skinner, London Business School, will take us again to the mind of an investor and thereby help us to best prepare our pitch-presentation.

“Investment-hungry researchers can spend many hours on their pitch and still get it wrong. The problem is that they use their time to talk about the wrong things. The most common fault is time spent on the technology and market size – when the investor is wondering whether anybody really wants what you have created. This sends two messages – first that the researcher and investor are on different pages (not the best start to a relationship). Second that the researcher has stayed in his or her comfort zone (the laboratory) rather than engaging with potential users.

It turns out that investors are not that sophisticated. Of course they want an understanding of the technology and its potential. But they also want to know – and thus you to address (or at least, acknowledge) reasons why the venture might fail as a business and how you’re spending your time and energy to mitigate those risks. In this short session I want to shine a light on the way they think, using a specific example to develop a powerful framework for analysing venture risks and then using this as a lens to examine some of your own venture ideas.

By the end of the session you will, I hope, be in a far better position to structure your pitch in a way that intrigues investors sufficiently to continue the conversation.”

The webinar is open to all people, connected to our member-institutes and participating firms. 

You’re welcome to join us on September 19, 12.00 – 13.00 at a webinar hosted by Bioqube Ventures on how they deploy their venture creation model to guide academic entrepreneurs in focusing on the key steps that add most value in early stage ventures and set them up for future success. By working shoulder to shoulder with an investor, scientific founders gain the industry perspective from the get-go to anticipate pitfalls that a young start-up can encounter down the road. Aspects like optimally designing development plans and aligning your fundraising strategy, implementing a solid governance structure and identifying a clear IP strategy can make the difference between an academic start-up and an industry-proof biotech.

During this session you will get the scientific founder perspective from OncoSpear therapeutics and their experience in working together with Bioqube Ventures on their path from early-stage spin-off towards a focused preclinical-stage biotech.

On June 13 Pieter Roelfsema, founder of our alumni project Phosphoenix, will give a webinar focusing at The early development of a spin-off company that aims to make a visual prosthesis for the blind (title to be confirmed). Pieter will share with us his experiences in his journey from a researcher into an entrepreneur and the things he wishes he would have known before. Pieter will be accompanied by one of his investment managers.

Pieter R. Roelfsema received his MD degree in 1991 and his PhD degree in 1995. He moved to the Netherlands Institute for Neuroscience in Amsterdam in 2002 and became director in 2007. He is professor at the Free University of Amsterdam and at the AUMC in Amsterdam. He received a NWO-VICI award (2008) and two ERC-Advanced grants (2014 and 2022). Roelfsema studies visual perception, plasticity, memory and consciousness in the visual system of experimental animals, humans, and with neural networks. His main question is how neurons in different brain areas work together during seeing and thinking. Roelfsema studies how networks of neurons work together to perceive and solve cognitive tasks and how they configure themselves during learning. He develops the neurotechnology for high-bandwidth visual prostheses for blind people, aiming to restore a rudimentary form of sight. Roelfsema coordinates the Dutch neurotechnology initiative NeuroTech-NL. In 2019 he co-founded the start-up company Phosphoenix that aims to develop a visual brain prosthesis.

On Tuesday, 8 February, 12.00 – 13.00, we continued our free lunch webinar series by discussing the topic of Patent filing and prosecution strategy; from spin-off/start-up to a large company.

This edition focused on the different possible strategic choices when applying for a patent. The issue was addressed in the perspective of the importance of protection of the patent claims on the business development strategy, ranging from a spin off/start up to a large company. The topic was exemplified via specific practical IP cases.

The webinar was given by Nick Schopman from Arnold&Siedsma, a full service provider in the field of intellectual property. Nick has a background in Biotechnology and obtained his PhD in Immunology and Virology at the Amsterdam UMC.

A recorded version of the webinar is available for spin off teams, researchers and staff of HIHR-institutions. Other people, connected to our member institutions or participating firms are welcome to have a look as well. Please note that the webinars are for internal use only.

The 3rd and 4th free HIHR lunch webinar of 2021 was given by Qualix, a partner in Quality Assurance and Regulatory Affairs.

This online session gave an introduction on:

• IVDR/MDR legislative framework
• Regulatory roadmap for new MedTech projects
• Challenges to consider when bringing a medical device to the market

and was followed by a Q&A session.

The webinar was given by Pascale Van Hoydonck – senior consultant (long track record as EMEA Regulatory affairs director in MedTech industry) and/or Ruth Beckers – founder/senior consultant (long track record as quality and regulatory affairs consultant for MedTech industry) from Qualix.

A recorded version of the webinar is available for spin off teams, researchers and staff of HIHR-institutions. Other people, connected to our member institutions or participating firms are welcome to have a look as well.
Please note that the webinars are for internal use only.

The 3rd and 4th free HIHR lunch webinar of 2021 was given by Qualix, a partner in Quality Assurance and Regulatory Affairs.

This online session gave an introduction on:

• IVDR/MDR legislative framework
• Regulatory roadmap for new MedTech projects
• Challenges to consider when bringing a medical device to the market

and was followed by a Q&A session.

The webinar was given by Pascale Van Hoydonck – senior consultant (long track record as EMEA Regulatory affairs director in MedTech industry) and/or Ruth Beckers – founder/senior consultant (long track record as quality and regulatory affairs consultant for MedTech industry) from Qualix.

A recorded version of the webinar is available for spin off teams, researchers and staff of HIHR-institutions. Other people, connected to our member institutions or participating firms are welcome to have a look as well.
Please note that the webinars are for internal use only.

A recorded version of the webinar is available for spin off teams and staff of HIHR-institutions for internal use only.
Please send an email to claar-els@hihr.eu to receive the link.

The webinar, hosted by INKEF Capital, an early stage VC in technology and healthcare, provides an inside look into the venture capital decision making process and its key drivers. The speakers Ivan Burkov and Simone Botti bring up a few real-life cases that exemplify the concept of “investability” and showcase how one can approach potential project planning to maximize its chances of securing funding.

The program consists of a presentation of 45 minutes on the following topics:

• intro on Inkef
• three important things to take into account when starting a biotech
• the VC world
• what do investors look for and how to maximize your fundraising chance

followed by 15 to 20 minutes Q&A.

Scope of the webinar is how to prepare an IP Due Diligence; pitfalls and take home messages, plus the merit of having this in place to strengthen your file for investors.

Three short modules of 15 minutes each will deal with:

1. Data Rooms and what it takes to manage this: When do you start building the data room? What requirements must it meet? How does an IP due diligence work?
2. DD on patents / FTO (Freedom to Operate): What ways are there to perform an FTO? Why is this so important? What requirements must the FTO meet?
3. DD on IP Contracts: What should you pay attention to? What are the pitfalls and what conditions do you have to meet?

The webinar was hosted by Arnold & Siedsma / LC Patents, a full service provider in the field of intellectual property. And the presentation was given by Nick Schopman and Michiel Rijsdijk, partner and attorney-at-law at Arnold & Siedsma / LC Patents. Nick is a European and Dutch patent attorney and has a background in Biotechnology and obtained his PhD in Immunology and Virology at the Amsterdam Medical Centre.

A recorded version of the webinar is available for spin-off teams and staff of HIHR-institutions for internal use only. Please send an email to claar-els@hihr.eu to receive the link.